Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

There is also pembrolizumab, but this agent has to be given intravenously, potentially exposing the patient to more toxicity ...

Bicycle Therapeutics plc, a company specializing in developing therapeutic solutions based on its proprietary bicyclic peptide technology, revealed significant data updates across its zelenectide ...